Search

Your search keyword '"Reddy, Chandana"' showing total 964 results
Start Over Author "Reddy, Chandana"
964 results on '"Reddy, Chandana"'

1. Neutrophil to lymphocyte ratio (NTLR) predicts local control and overall survival after stereotactic body radiotherapy (SBRT) in metastatic sarcoma

Author

Somasundaram, Eashwar, Anderson, Peter M., Smile, Timothy D., Halima, Ahmed, Broughman, James B., Reddy, Chandana A., Parsai, Shireen, Scott, Jacob G., Chan, Timothy, Campbell, Shauna, Angelov, Lilyana, Zahler, Stacey, Trucco, Matteo, Thomas, Stefanie M., Johnson, Shavaughn, Qi, Peng, Magnelli, Anthony, and Murphy, Erin S.

Published
2023
Full Text
View/download PDF

2. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer

Author

Kishan, Amar U, Steigler, Alison, Denham, James W, Zapatero, Almudena, Guerrero, Araceli, Joseph, David, Maldonado, Xavier, Wong, Jessica K, Stish, Bradley J, Dess, Robert T, Pilar, Avinash, Reddy, Chandana, Wedde, Trude B, Lilleby, Wolfgang A, Fiano, Ryan, Merrick, Gregory S, Stock, Richard G, Demanes, D Jeffrey, Moran, Brian J, Tran, Phuoc T, Martin, Santiago, Martinez-Monge, Rafael, Krauss, Daniel J, Abu-Isa, Eyad I, Pisansky, Thomas M, Choo, C Richard, Song, Daniel Y, Greco, Stephen, Deville, Curtiland, McNutt, Todd, DeWeese, Theodore L, Ross, Ashley E, Ciezki, Jay P, Tilki, Derya, Karnes, R Jeffrey, Tosoian, Jeffrey J, Nickols, Nicholas G, Bhat, Prashant, Shabsovich, David, Juarez, Jesus E, Jiang, Tommy, Ma, T Martin, Xiang, Michael, Philipson, Rebecca, Chang, Albert, Kupelian, Patrick A, Rettig, Matthew B, Feng, Felix Y, Berlin, Alejandro, Tward, Jonathan D, Davis, Brian J, Reiter, Robert E, Steinberg, Michael L, Elashoff, David, Boutros, Paul C, Horwitz, Eric M, Tendulkar, Rahul D, Spratt, Daniel E, and Romero, Tahmineh

Subjects
Cancer, Clinical Research, Prostate Cancer, Urologic Diseases, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Androgen Antagonists, Androgens, Brachytherapy, Data Analysis, Humans, Male, Middle Aged, Prostatic Neoplasms, Retrospective Studies, Oncology and Carcinogenesis, Public Health and Health Services
Abstract

ImportanceRadiotherapy combined with androgen deprivation therapy (ADT) is a standard of care for high-risk prostate cancer. However, the interplay between radiotherapy dose and the required minimum duration of ADT is uncertain.ObjectiveTo determine the specific ADT duration threshold that provides a distant metastasis-free survival (DMFS) benefit in patients with high-risk prostate cancer receiving external beam radiotherapy (EBRT) or EBRT with a brachytherapy boost (EBRT+BT).Design, settings, and participantsThis was a cohort study of 3 cohorts assembled from a multicenter retrospective study (2000-2013); a post hoc analysis of the Randomized Androgen Deprivation and Radiotherapy 03/04 (RADAR; 2003-2007) randomized clinical trial (RCT); and a cross-trial comparison of the RADAR vs the Deprivación Androgénica y Radio Terapía (Androgen Deprivation and Radiation Therapy; DART) 01/05 RCT (2005-2010). In all, the study analyzed 1827 patients treated with EBRT and 1108 patients treated with EBRT+BT from the retrospective cohort; 181 treated with EBRT and 203 with EBRT+BT from RADAR; and 91 patients treated with EBRT from DART. The study was conducted from October 15, 2020, to July 1, 2021, and the data analyses, from January 5 to June 15, 2021.ExposuresHigh-dose EBRT or EBRT+BT for an ADT duration determined by patient-physician choice (retrospective) or by randomization (RCTs).Main outcomes and measuresThe primary outcome was DMFS; secondary outcome was overall survival (OS). Natural cubic spline analysis identified minimum thresholds (months).ResultsThis cohort study of 3 studies totaling 3410 men (mean age [SD], 68 [62-74] years; race and ethnicity not collected) with high-risk prostate cancer found a significant interaction between the treatment type (EBRT vs EBRT+BT) and ADT duration (binned to

Published
2022

4. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography–Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer

Author

Xiang, Michael, Martin, Ting, Savjani, Ricky, Pollom, Erqi L, Karnes, R Jeffrey, Grogan, Tristan, Wong, Jessica K, Motterle, Giovanni, Tosoian, Jeffrey J, Trock, Bruce J, Klein, Eric A, Stish, Bradley J, Dess, Robert T, Spratt, Daniel E, Pilar, Avinash, Reddy, Chandana, Levin-Epstein, Rebecca, Wedde, Trude B, Lilleby, Wolfgang A, Fiano, Ryan, Merrick, Gregory S, Stock, Richard G, Demanes, D Jeffrey, Moran, Brian J, Huland, Hartwig, Tran, Phuoc T, Martin, Santiago, Martinez-Monge, Rafael, Krauss, Daniel J, Abu-Isa, Eyad I, Alam, Ridwan, Schwen, Zeyad, Pisansky, Thomas M, Choo, C Richard, Song, Daniel Y, Greco, Stephen, Deville, Curtiland, McNutt, Todd, DeWeese, Theodore L, Ross, Ashley E, Ciezki, Jay P, Boutros, Paul C, Nickols, Nicholas G, Bhat, Prashant, Shabsovich, David, Juarez, Jesus E, Chong, Natalie, Kupelian, Patrick A, Rettig, Matthew B, Zaorsky, Nicholas G, Berlin, Alejandro, Tward, Jonathan D, Davis, Brian J, Reiter, Robert E, Steinberg, Michael L, Elashoff, David, Horwitz, Eric M, Tendulkar, Rahul D, Tilki, Derya, Czernin, Johannes, Gafita, Andrei, Romero, Tahmineh, Calais, Jeremie, and Kishan, Amar U

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Biomedical Imaging, Prostate Cancer, Cancer, Clinical Research, Urologic Diseases, Aging, Prevention, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Good Health and Well Being, Adult, Aged, Aged, 80 and over, Antigens, Surface, Biomarkers, Tumor, Clinical Decision Rules, Follow-Up Studies, Glutamate Carboxypeptidase II, Humans, Male, Middle Aged, Neoplasm Staging, Nomograms, Positron Emission Tomography Computed Tomography, Prognosis, Prostatic Neoplasms, Retrospective Studies, Risk Assessment, SEER Program, Survival Analysis, Biomedical and clinical sciences, Health sciences
Abstract

ImportanceProstate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) can detect low-volume, nonlocalized (ie, regional or metastatic) prostate cancer that was occult on conventional imaging. However, the long-term clinical implications of PSMA PET/CT upstaging remain unclear.ObjectivesTo evaluate the prognostic significance of a nomogram that models an individual's risk of nonlocalized upstaging on PSMA PET/CT and to compare its performance with existing risk-stratification tools.Design, setting, and participantsThis cohort study included patients diagnosed with high-risk or very high-risk prostate cancer (ie, prostate-specific antigen [PSA] level >20 ng/mL, Gleason score 8-10, and/or clinical stage T3-T4, without evidence of nodal or metastatic disease by conventional workup) from April 1995 to August 2018. This multinational study was conducted at 15 centers. Data were analyzed from December 2020 to March 2021.ExposuresCurative-intent radical prostatectomy (RP), external beam radiotherapy (EBRT), or EBRT plus brachytherapy (BT), with or without androgen deprivation therapy.Main outcomes and measuresPSMA upstage probability was calculated from a nomogram using the biopsy Gleason score, percentage positive systematic biopsy cores, clinical T category, and PSA level. Biochemical recurrence (BCR), distant metastasis (DM), prostate cancer-specific mortality (PCSM), and overall survival (OS) were analyzed using Fine-Gray and Cox regressions. Model performance was quantified with the concordance (C) index.ResultsOf 5275 patients, the median (IQR) age was 66 (60-72) years; 2883 (55%) were treated with RP, 1669 (32%) with EBRT, and 723 (14%) with EBRT plus BT; median (IQR) PSA level was 10.5 (5.9-23.2) ng/mL; 3987 (76%) had Gleason grade 8 to 10 disease; and 750 (14%) had stage T3 to T4 disease. Median (IQR) follow-up was 5.1 (3.1-7.9) years; 1221 (23%) were followed up for at least 8 years. Overall, 1895 (36%) had BCR, 851 (16%) developed DM, and 242 (5%) died of prostate cancer. PSMA upstage probability was significantly prognostic of all clinical end points, with 8-year C indices of 0.63 (95% CI, 0.61-0.65) for BCR, 0.69 (95% CI, 0.66-0.71) for DM, 0.71 (95% CI, 0.67-0.75) for PCSM, and 0.60 (95% CI, 0.57-0.62) for PCSM (P

Published
2021

5. Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer

Author

Philipson, Rebecca G, Romero, Tahmineh, Wong, Jessica K, Stish, Bradley J, Dess, Robert T, Spratt, Daniel E, Pilar, Avinash, Reddy, Chandana, Wedde, Trude B, Lilleby, Wolfgang A, Fiano, Ryan, Merrick, Gregory S, Stock, Richard G, Demanes, D Jeffrey, Moran, Brian J, Braccioforte, Michelle, Tran, Phuoc T, Martin, Santiago, Martinez-Monge, Rafael, Krauss, Daniel J, Abu-Isa, Eyad I, Valle, Luca, Chong, Natalie, Pisansky, Thomas M, Choo, C Richard, Song, Daniel Y, Greco, Stephen, Deville, Curtiland, McNutt, Todd, DeWeese, Theodore L, Ross, Ashley E, Ciezki, Jay P, Tilki, Derya, Karnes, R Jeffrey, Klein, Eric A, Tosoian, Jeffrey J, Boutros, Paul C, Nickols, Nicholas G, Bhat, Prashant, Shabsovich, David, Juarez, Jesus E, Kupelian, Patrick A, Rettig, Matthew B, Berlin, Alejandro, Tward, Jonathan D, Davis, Brian J, Reiter, Robert E, Steinberg, Michael L, Elashoff, David, Horwitz, Eric M, Tendulkar, Rahul D, and Kishan, Amar U

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Prevention, Urologic Diseases, Prostate Cancer, Cancer, Clinical Research, Aging, Brachytherapy, Humans, Male, Neoplasm Grading, Prostate, Prostatic Neoplasms, Salvage Therapy, Biochemical recurrence, Brachytherapy boost, EBRT, External beam radiation therapy, High-risk prostate cancer, Prostate cancer, Radiorecurrence, Recurrent prostate cancer, Urology & Nephrology, Clinical sciences
Abstract

The natural history of radiorecurrent high-risk prostate cancer (HRPCa) is not well-described. To better understand its clinical course, we evaluated rates of distant metastases (DM) and prostate cancer-specific mortality (PCSM) in a cohort of 978 men with radiorecurrent HRPCa who previously received either external beam radiation therapy (EBRT, n = 654, 67%) or EBRT + brachytherapy (EBRT + BT, n = 324, 33%) across 15 institutions from 1997 to 2015. In men who did not die, median follow-up after treatment was 8.9 yr and median follow-up after biochemical recurrence (BCR) was 3.7 yr. Local and systemic therapy salvage, respectively, were delivered to 21 and 390 men after EBRT, and eight and 103 men after EBRT + BT. Overall, 435 men developed DM, and 248 were detected within 1 yr of BCR. Measured from time of recurrence, 5-yr DM rates were 50% and 34% after EBRT and EBRT + BT, respectively. Measured from BCR, 5-yr PCSM rates were 27% and 29%, respectively. Interval to BCR was independently associated with DM (p

Published
2021

7. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis

Author

Sandler, Kiri A, Cook, Ryan R, Ciezki, Jay P, Ross, Ashley E, Pomerantz, Mark M, Nguyen, Paul L, Shaikh, Talha, Tran, Phuoc T, Stock, Richard G, Merrick, Gregory S, Demanes, David Jeffrey, Spratt, Daniel E, Abu-Isa, Eyad I, Wedde, Trude B, Lilleby, Wolfgang, Krauss, Daniel J, Shaw, Grace K, Alam, Ridwan, Reddy, Chandana A, Song, Daniel Y, Klein, Eric A, Stephenson, Andrew J, Tosoian, Jeffrey J, Hegde, John V, Yoo, Sun Mi, Fiano, Ryan, D'Amico, Anthony V, Nickols, Nicholas G, Aronson, William J, Sadeghi, Ahmad, Greco, Stephen C, Deville, Curtiland, McNutt, Todd, DeWeese, Theodore L, Reiter, Robert E, Said, Jonathan W, Steinberg, Michael L, Horwitz, Eric M, Kupelian, Patrick A, King, Christopher R, and Kishan, Amar U

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Trials and Supportive Activities, Prostate Cancer, Clinical Research, Urologic Diseases, Aging, Aged, Brachytherapy, Hemibody Irradiation, Humans, Male, Neoplasm Grading, Pelvis, Prostate, Prostatic Neoplasms, Retrospective Studies, Survival Rate, Gleason grade group 5, Prostate cancer, Radiation therapy, Whole-pelvis irradiation, Urology & Nephrology, Clinical sciences
Abstract

BackgroundThe role of elective whole-pelvis radiotherapy (WPRT) remains controversial. Few studies have investigated it in Gleason grade group (GG) 5 prostate cancer (PCa), known to have a high risk of nodal metastases.ObjectiveTo assess the impact of WPRT on patients with GG 5 PCa treated with external-beam radiotherapy (EBRT) or EBRT with a brachytherapy boost (EBRT+BT).Design, setting, and participantsWe identified 1170 patients with biopsy-proven GG 5 PCa from 11 centers in the United States and one in Norway treated between 2000 and 2013 (734 with EBRT and 436 with EBRT+BT).Outcome measurements and statistical analysisBiochemical recurrence-free survival (bRFS), distant metastasis-free survival (DMFS), and prostate cancer-specific survival (PCSS) were compared using Cox proportional hazards models with propensity score adjustment.Results and limitationsA total of 299 EBRT patients (41%) and 320 EBRT+BT patients (73%) received WPRT. The adjusted 5-yr bRFS rates with WPRT in the EBRT and EBRT+BT groups were 66% and 88%, respectively. Without WPRT, these rates for the EBRT and EBRT+BT groups were 58% and 78%, respectively. The median follow-up was 5.6yr. WPRT was associated with improved bRFS among patients treated with EBRT+BT (hazard ratio [HR] 0.5, 95% confidence interval [CI] 0.2-0.9, p=0.02), but no evidence for improvement was found in those treated with EBRT (HR 0.8, 95% CI 0.6-1.2, p=0.4). WPRT was not significantly associated with improved DMFS or PCSS in the EBRT group (HR 1.1, 95% CI 0.7-1.7, p=0.8 for DMFS and HR 0.7, 95% CI 0.4-1.1, p=0.1 for PCSS), or in the EBRT+BT group (HR 0.6, 95% CI 0.3-1.4, p=0.2 for DMFS and HR 0.5 95% CI 0.2-1.2, p=0.1 for PCSS).ConclusionsWPRT was not associated with improved PCSS or DMFS in patients with GG 5 PCa who received either EBRT or EBRT+BT. However, WPRT was associated with a significant improvement in bRFS among patients receiving EBRT+BT. Strategies to optimize WPRT, potentially with the use of advanced imaging techniques to identify occult nodal disease, are warranted.Patient summaryWhen men with a high Gleason grade prostate cancer receive radiation with external radiation and brachytherapy, the addition of radiation to the pelvis results in a longer duration of prostate-specific antigen control. However, we did not find a difference in their survival from prostate cancer or in their survival without metastatic disease. We also did not find a benefit for radiation to the pelvis in men who received radiation without brachytherapy.

Published
2020

8. External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis

Author

Patel, Sagar A., Ma, Ting Martin, Wong, Jessica K., Stish, Bradley J., Dess, Robert T., Pilar, Avinash, Reddy, Chandana, Wedde, Trude B., Lilleby, Wolfgang A., Fiano, Ryan, Merrick, Gregory S., Stock, Richard G., Demanes, D. Jeffrey, Moran, Brian J., Tran, Phuoc T., Krauss, Daniel J., Abu-Isa, Eyad I., Pisansky, Thomas M., Choo, C. Richard, Song, Daniel Y., Greco, Stephen, Deville, Curtiland, DeWeese, Theodore L., Tilki, Derya, Ciezki, Jay P., Karnes, R. Jeffrey, Nickols, Nicholas G., Rettig, Matthew B., Feng, Felix Y., Berlin, Alejandro, Tward, Jonathan D., Davis, Brian J., Reiter, Robert E., Boutros, Paul C., Romero, Tahmineh, Horwitz, Eric M., Tendulkar, Rahul D., Steinberg, Michael L., Spratt, Daniel E., Xiang, Michael, and Kishan, Amar U.

Published
2023
Full Text
View/download PDF

11. Intratumoral androgen biosynthesis associated with 3[beta]-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer

Author

Ganguly, Shinjini, Lone, Zaeem, Muskara, Andrew, Imamura, Jarrell, Hardaway, Aimalie, Patel, Mona, Berk, Mike, Smile, Timothy D., Davicioni, Elai, Stephans, Kevin L., Ciezki, Jay, Weight, Christopher J., Gupta, Shilpa, Reddy, Chandana A., Tendulkar, Rahul D., Chakraborty, Abhishek A., Klein, Eric A., Sharifi, Nima, and Mian, Omar Y.

Subjects
Thermo Fisher Scientific Inc., Life Technologies Corp., DNA repair -- Genetic aspects -- Research -- Physiological aspects, Dehydroepiandrosterone -- Research, Scientific equipment and supplies industry -- Physiological aspects -- Genetic aspects -- Research, Gene expression -- Research -- Physiological aspects -- Genetic aspects, Prostate cancer -- Development and progression -- Research -- Genetic aspects, Genes -- Physiological aspects -- Genetic aspects -- Research, Biotechnology industry -- Physiological aspects -- Research -- Genetic aspects, Androgens -- Research, DNA damage -- Physiological aspects -- Genetic aspects -- Research, Radiotherapy -- Physiological aspects -- Research, Health care industry, Cleveland Clinic
Abstract

Half of all men with advanced prostate cancer (PCa) inherit at least 1 copy of an adrenal-permissive HSD3B1 (1245C) allele, which increases levels of 3[beta]-hydroxysteroid dehydrogenase 1 (3[beta]HSD1) and promotes intracellular androgen biosynthesis. Germline inheritance of the adrenally permissive allele confers worse outcomes in men with advanced PCa. We investigated whether H5D3S7 (1245C) drives resistance to combined androgen deprivation and radiotherapy. Adrenally permissive 3[beta]HSD1 enhanced resistance to radiotherapy in PCa cell lines and xenograft models engineered to mimic the human adrenal/gonadal axis during androgen deprivation. The allele-specific effects on radiosensitivity were dependent on availability of DHEA, the substrate for 3[beta]HSD1. In lines expressing the HSD3B1 (1245C) allele, enhanced expression of DNA damage response (DDR) genes and more rapid DNA double-strand break (DSB) resolution were observed. A correlation between androgen receptor (AR) expression and increased DDR gene expression was confirmed in 680 radical prostatectomy specimens. Treatment with the nonsteroidal antiandrogen enzalutamide reversed the resistant phenotype of HSD3B1 (1245C) PCa in vitro and in vivo. In conclusion, 3[beta]HSD1 promotes prostate cancer resistance to combined androgen deprivation and radiotherapy by upregulating ?NA DSB repair. This work supports prospective validation of early combined androgen blockade for high-risk men harboring the HSD3B1 (1245C) allele., Introduction In men with high-grade prostate cancer (PCa) treated with curative-intent radiotherapy, the addition of androgen-deprivation therapy (ADT) confers a clear and sustained benefit in terms of local control, metastasis-free [...]

Published
2023
Full Text
View/download PDF

12. Independent blinded validation of an AI-based digital histology classifier for prostate cancer recurrence and metastasis risk prediction.

Author

Fay, Magdalena, primary, Liao, Ross, additional, Lone, Zaeem M, additional, Reddy, Chandana A., additional, Muhammad, Hassan, additional, Xie, Chensu, additional, Jain, Parag, additional, Huang, Wei, additional, Basu, Hirak S, additional, Nguyen, Jane, additional, Nair, Sujit S., additional, Chakravarty, Dimple, additional, Williamson, Sean R., additional, Gupta, Shilpa, additional, Weight, Christopher, additional, Roy, Rajat, additional, Wilding, George, additional, Tewari, Ashutosh K., additional, Klein, Eric A., additional, and Mian, Omar Y., additional

Published
2024
Full Text
View/download PDF

14. Primary fit tracheoesophageal puncture in primary versus salvage laryngectomy: Short‐term and long‐term complications and functional outcomes.

Author

Kanyo, Emese C., Wu, Shannon S., Reddy, Chandana A., Silver, Natalie L., Lamarre, Eric D., Burkey, Brian B., Prendes, Brandon L., Scharpf, Joseph, Lorenz, Robert R., Kmiecik, Joann, and Ku, Jamie A.

Subjects
LARYNGEAL cancer, CANCER prognosis, FUNCTIONAL status, LARYNGECTOMY, FISTULA, PROSTHETICS
Abstract

Background: Primary fit tracheoesophageal puncture (TEP) is widely preferred for individuals who have not undergone prior radiation. However, there is no consensus on the relative utility of primary‐fit TEP in the setting of salvage laryngectomy. Methods: A retrospective, single‐center review was conducted of individuals undergoing laryngectomy with primary fit TEP between 2012 and 2018. Multivariable analysis was conducted to compare short‐term and long‐term complications, as well as speech and swallowing outcomes, of those who underwent primary versus salvage laryngectomy. Results: In this study, 134 patients underwent total laryngectomy with primary fit TEP. Aside from a higher rate of peristomal dehiscence (13.1% vs. 1.4%) found in the salvage group, there was no difference in incidence of all other complications, including pharyngocutaneous fistula formation. The groups had comparable speech and swallow outcomes. Conclusion: Primary fit TEP is a safe and effective surgical choice for individuals undergoing salvage laryngectomy who desire a voice prosthesis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Evaluating the impact of the degree of extranodal extension on outcomes in locally advanced oral cavity cancer.

Author

Yalamanchali, Anirudh, Griffith, Christopher, Reddy, Chandana A., Koyfman, Shlomo A., Woody, Neil M., Campbell, Shauna R., Silver, Natalie, Scharpf, Joseph, Lorenz, Robert R., Prendes, Brandon, Ku, Jamie A., Lamarre, Eric, and Geiger, Jessica L.

Subjects
SQUAMOUS cell carcinoma, ORAL cancer, OVERALL survival, DATABASES, CANCER cells
Abstract

Background: Evaluate whether extranodal extension (ENE) extent impacts outcomes in patients with oral cavity squamous cell carcinoma (OCSCC). Methods: From an institutional database, patients with OCSCC and pathologic ENE who received adjuvant treatment were included. Surgical slides were reviewed to confirm ENE extent. Multivariable Cox regression was used to relate patient/treatment characteristics with disease‐free survival (DFS) and overall survival (OS). ENE was analyzed as both a dichotomous and continuous variable. Results: A total of 113 patients were identified. Between major (>2 mm) versus minor ENE (≤2 mm), there was no significant difference in DFS (HR 1.18, 95%CI 0.72–1.92, p = 0.51) or OS (HR 1.17, 95%CI 0.70–1.96, p = 0.55). There was no significant association between ENE as a continuous variable and DFS (HR 0.97 per mm, 95%CI 0.87–1.4, p = 0.96) or OS (HR 0.96 per mm, 95%CI 0.83–1.11, p = 0.58). Conclusion: No significant relationship was seen between ENE extent and DFS or OS in individuals with OCSCC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Risk Factors for Progression Among Low-Grade Gliomas After Gross Total Resection and Initial Observation in the Molecular Era

Author

Tom, Martin C., Varra, Vamsi, Leyrer, C. Marc, Park, Deborah Y., Chao, Samuel T., Yu, Jennifer S., Suh, John H., Reddy, Chandana A., Balagamwala, Ehsan H., Broughman, James R., Kotagal, Kiran A., Vogelbaum, Michael A., Barnett, Gene H., Ahluwalia, Manmeet S., Peereboom, David M., Prayson, Richard A., Stevens, Glen H.J., and Murphy, Erin S.

Published
2019
Full Text
View/download PDF

31. Margin Assessment Methods in Oral Cavity Squamous Cell Carcinoma and Recurrence

Author

Wu, Shannon S., primary, Woody, Neil, additional, Hesse, Jennifer, additional, Cook, Samantha, additional, Cracolici, Vincent, additional, Ku, Jamie A., additional, Prendes, Brandon, additional, Silver, Natalie, additional, Scharpf, Joseph, additional, Brauer, Philip R., additional, Reddy, Chandana A., additional, Campbell, Shauna R., additional, Koyfman, Shlomo A., additional, Burkey, Brian, additional, and Lamarre, Eric D., additional

Published
2023
Full Text
View/download PDF

32. Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study

Author

Sandler, Kiri A., Cook, Ryan R., Ciezki, Jay P., Ross, Ashley E., Pomerantz, Mark M., Nguyen, Paul L., Shaikh, Talha, Tran, Phuoc T., Stock, Richard G., Merrick, Gregory S., Demanes, D. Jeffrey, Spratt, Daniel E., Abu-Isa, Eyad I., Wedde, Trude B., Lilleby, Wolfgang, Krauss, Daniel J., Shaw, Grace K., Alam, Ridwan, Reddy, Chandana A., Song, Daniel Y., Klein, Eric A., Stephenson, Andrew J., Tosoian, Jeffrey J., Hegde, John V., Yoo, Sun Mi, Fiano, Ryan, D'Amico, Anthony V., Nickols, Nicholas G., Aronson, William J., Sadeghi, Ahmad, Greco, Stephen C., Deville, Curtiland, McNutt, Todd, DeWeese, Theodore L., Reiter, Robert E., Said, Jonathan W., Steinberg, Michael L., Horwitz, Eric M., Kupelian, Patrick A., King, Christopher R., and Kishan, Amar U.

Published
2018
Full Text
View/download PDF

33. Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative

Author

Ward, Matthew C., Riaz, Nadeem, Caudell, Jimmy J., Dunlap, Neal E., Isrow, Derek, Zakem, Sara J., Dault, Joshua, Awan, Musaddiq J., Vargo, John A., Heron, Dwight E., Higgins, Kristin A., Beitler, Jonathan J., Marcrom, Samuel, Boggs, Drexell H., Hassanzadeh, Comron, Reddy, Chandana A., Bonner, James A., Yao, Min, Machtay, Mitchell, Siddiqui, Farzan, Trotti, Andy M., Lee, Nancy Y., and Koyfman, Shlomo A.

Published
2018
Full Text
View/download PDF

34. Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis

Author

Caudell, Jimmy J., Ward, Matthew C., Riaz, Nadeem, Zakem, Sara J., Awan, Musaddiq J., Dunlap, Neal E., Isrow, Derek, Hassanzadeh, Comron, Vargo, John A., Heron, Dwight E., Marcrom, Samuel, Boggs, Drexell H., Reddy, Chandana A., Dault, Joshua, Bonner, James A., Higgins, Kristin A., Beitler, Jonathan J., Koyfman, Shlomo A., Machtay, Mitchell, Yao, Min, Trotti, Andy M., Siddiqui, Farzan, and Lee, Nancy Y.

Published
2018
Full Text
View/download PDF

35. A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer

Author

Vargo, John A., Ward, Matthew C., Caudell, Jimmy J., Riaz, Nadeem, Dunlap, Neal E., Isrow, Derek, Zakem, Sara J., Dault, Joshua, Awan, Musaddiq J., Higgins, Kristin A., Hassanadeh, Comron, Beitler, Jonathan J., Reddy, Chandana A., Marcrom, Samuel, Boggs, Drexell H., Bonner, James A., Yao, Min, Machtay, Mitchell, Siddiqui, Farzan, Trotti, Andy M., Lee, Nancy Y., Koyfman, Shlomo A., Ferris, Robert L., and Heron, Dwight E.

Published
2018
Full Text
View/download PDF

39. Long-Term (10-Year) Gastrointestinal and Genitourinary Toxicity after Treatment with External Beam Radiotherapy, Radical Prostatectomy, or Brachytherapy for Prostate Cancer

Author

Hunter, Grant K, Reddy, Chandana A, Klein, Eric A, Kupelian, Patrick, Angermeier, Kenneth, Ulchaker, James, Chehade, Nabil, Altman, Andrew, and Ciezki, Jay P

Subjects
Digestive Diseases, Cancer, Urologic Diseases, Prostate Cancer, Patient Safety, Oncology and Carcinogenesis
Abstract

Objective.To examine gastrointestinal (GI) and genitourinary (GU) toxicity profiles of patients treated in 1999 with external beam radiotherapy (RT), prostate interstitial brachytherapy (PI) or radical prostatectomy (RP). Methods. TThe records of 525 patients treated in 1999 were reviewed to evaluate toxicity. Late GI and GU morbidities were graded according to the RTOG late morbidity criteria. Other factors examined were patient age, BMI, smoking history, and medical co-morbidities. Due to the low event rate for late GU and GI toxicities, a competing risk regression (CRR) analysis was done with death as the competing event. Results. Median follow-up time was 8.5 years. On CRR univariate analysis, only the presence of DM was significantly associated with GU toxicity grade >2 (P = 0.43, HR 2.35, 95% Cl = 1.03-5.39). On univariate analysis, RT and DM were significantly associated with late GI toxicity. On multivariable analysis, both variables remained significant (RT: P = 0.038, HR = 4.71, CI = 1.09-20.3; DM: P = 0.008, HR = 3.81, 95% Cl = 1.42-10.2). Conclusions. Late effects occur with all treatment modalities. The presence of DM at the time of treatment was significantly associated with worse late GI and GU toxicity. RT was significantly associated with worse late GI toxicity compared to PI and RP.

Published
2012

40. Neutrophil to Lymphocyte Ratio (NTLR) Predicts Local Control Failure and Overall Survival after Stereotactic Body Radiotherapy (SBRT) in Metastatic Sarcoma

Author

Somasundaram, Eashwar, primary, Smile, Timothy D, additional, Halima, Ahmed, additional, Broughman, James B, additional, Reddy, Chandana A, additional, Parsai, Shireen, additional, Scott, Jacob G, additional, Chan, Timothy, additional, Campbell, Shauna, additional, Angelov, Lilyana, additional, Zahler, Stacey, additional, Trucco, Matteo, additional, Thomas, Stefanie M, additional, Johnson, Shavaughn, additional, Qi, Peng, additional, Magnelli, Anthony, additional, Anderson, Peter M., additional, and Murphy, Erin S., additional

Published
2023
Full Text
View/download PDF

45. A Comparison Between Low-Dose-Rate Brachytherapy With or Without Androgen Deprivation, External Beam Radiation Therapy With or Without Androgen Deprivation, and Radical Prostatectomy With or Without Adjuvant or Salvage Radiation Therapy for High-Risk Prostate Cancer

Author

Ciezki, Jay P., Weller, Michael, Reddy, Chandana A., Kittel, Jeffrey, Singh, Harguneet, Tendulkar, Rahul, Stephans, Kevin L., Ulchaker, James, Angermeier, Kenneth, Stephenson, Andrew, Campbell, Steven, Haber, Georges-Pascal, and Klein, Eric A.

Published
2017
Full Text
View/download PDF

50. Association of Treatment Strategies and Tumor Characteristics With Overall Survival Among Patients With Anaplastic Thyroid Cancer

Author

Wu, Shannon S., primary, Lamarre, Eric D., additional, Yalamanchali, Anirudh, additional, Brauer, Philip R., additional, Hong, Hanna, additional, Reddy, Chandana A., additional, Yilmaz, Emrullah, additional, Woody, Neil, additional, Ku, Jamie A., additional, Prendes, Brandon, additional, Burkey, Brian, additional, Nasr, Christian, additional, Skugor, Mario, additional, Heiden, Katherine, additional, Chute, Deborah J., additional, Knauf, Jeffrey A., additional, Campbell, Shauna R., additional, Koyfman, Shlomo A., additional, Geiger, Jessica L., additional, and Scharpf, Joseph, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results